Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PER-001 intravitreal implant is a first-in-class small molecule in a sustained release proprietary delivery platform that selectively targets inhibition of the endothelin pathway, which is investigated for the treatment of diabetic retinopathy.
Lead Product(s): PER-001
Therapeutic Area: Ophthalmology Product Name: PER-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
PER-001 intravitreal implant is a novel (NCE), first-in-class small molecule endothelin receptor antagonist, which is being investigated for the treatment of Glaucoma.
Lead Product(s): PER-001
Therapeutic Area: Ophthalmology Product Name: PER-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
PER-001 is a first-in-class small molecule in a sustained release proprietary delivery platform that selectively targets inhibition of the endothelin pathway. PER-001, an intravitreal implant used for treatment in patients with advanced glaucoma.
Lead Product(s): PER-001
Therapeutic Area: Ophthalmology Product Name: PER-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023